Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-05-20

Study Completion Date

2018-07-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates two different methods for monitoring a patient's anti-clotting \[heparin\] therapy after they receive a heart pump implant \[left ventricular assist device -LVAD\]. One method tests for how long it takes the patient's blood to clot and uses that to determine if they are on the right dose of heparin. The other method uses a more direct measure of how much heparin is in the blood. The hypothesis is that the method that more directly measures how much heparin is in the patient's blood will provide better medical results for the patient's care after they have the heart pump implant. To that end, the investigators are conducting this feasibility trial to establish the logistics associated with the implementation of these heparin monitoring approaches.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Association of Anti-factor Xa Activity With Venous Thromboembolism in Critically Ill Patients

NCT06357403

Thrombosis Pulmonary Embolism Enoxaparin

RECRUITING

PREVENtion of HeartMate II Pump Thrombosis

NCT02158403

HeartMate II Pump Thrombosis

COMPLETED NA

Study to Test the Accuracy of a Prototype Handheld PT/INR Device

NCT01349712

Blood Coagulation Disorders

UNKNOWN

Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose

NCT02704052

Deep Venous Thrombosis Pulmonary Embolus Venous Thromboembolism

COMPLETED EARLY_PHASE1

3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE

NCT00365950

Deep Vein Thrombosis Pulmonary Embolism Deep Vein Thrombosis With Pulmonary Embolism

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Heart failure is a medical condition that is on the rise in the US and is associated with an enormous cost of $30 billion in healthcare expenses. People with heart failure may be treated with an LVAD that is connected to their heart and helps it pump the blood from the left side of the heart into the blood vessels that delivers blood to the body. These devices can be used to treat heart failure for the long term or they can be used while a patient waits for a heart transplant. In either case, the use of these devices is increasing.

One of the primary risks associated with LVADs are those related to blood clotting. Maintenance of the LVAD depends on preventing blood clots especially right after the surgery that puts them in place. This requires putting patients with LVADs on blood thinners and then monitoring the blood thinner levels carefully so that they don't have problems with bleeding too easily or, on the other hand, forming blood clots if they aren't on the right dose of blood thinners. Excessive bleeding - called hemorrhaging - is the more common problem after surgery and half of all patients that receive an LVAD will require a blood transfusion within the first 30 days after they receive the device. A laboratory test that measures how quickly blood clots is used to determine if the patient has the right amount of blood thinners. The current standard test is called "activated partial thromboplastin time \[aPTT\]." There are problems with the reliability of this test because it reacts with other elements in the blood. Alternately, there is a test that more directly measures the amount of heparin blood thinner rather than coagulation time and may be more reliable than aPTT called anti-factor Xa \[anti-Xa\].

The investigators have developed process diagrams that show steps for making decisions \[called nomograms\] that tell a nurse or doctor how to manage the heparin levels using test results from the aPTT test or the anti-Xa test; however, both tests will be performed at each decision time point, but the care team will only be told the results from the testing to which their patient is assigned.

The purpose of this feasibility study is to establish feasibility of using the two nomograms to determine which provides the optimal clinical information for improving patients' outcomes that have had LVADs placed.

Potential subjects will be recruited prior to their surgery and may decline to participate anytime before or after the surgery takes place. Subjects will be randomized to the aPTT nomogram or the anti-Xa nomogram. If they withdraw consent, they will receive the aPTT standard of care monitoring. The study procedures are performed by the clinical care team. Clinicians will be trained to use the nomograms.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Left Sided Heart Failure Left Ventricular Assist Device Anticoagulant Therapy Gastro Intestinal Bleeding Thrombosis, LVAD Anti-factor Xa aPTT Heparin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

aPTT nomogram

aPTT guided heparin management

Group Type ACTIVE_COMPARATOR

aPTT guided heparin management

Intervention Type DEVICE

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.

Anti-factor Xa guided heparin management

Intervention Type DEVICE

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device

Anti-factor Xa nomogram

Anti-factor Xa guided heparin management

Group Type EXPERIMENTAL

aPTT guided heparin management

Intervention Type DEVICE

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.

Anti-factor Xa guided heparin management

Intervention Type DEVICE

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

aPTT guided heparin management

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.

Intervention Type DEVICE

Anti-factor Xa guided heparin management

post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. 18 years of age and older
2. Implantation with HeartMate II® or HeartWare®, LVAD at Barnes Jewish Hospital

Exclusion Criteria

1. Unable to receive heparin-based therapy
2. Hypercoagulable disorders \[factor V Leiden, Antithrombin deficiency, Protein C deficiency, Antiphospholipid antibodies or other thrombophilia\]
3. Incarceration
4. Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No